Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner

(Reuters) – Pfizer intends to sell about 700 million ordinary shares in Haleon, cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.

(Reporting by Aatrayee Chatterjee; Editing by Shailesh Kuber)